Skip to main content
Equibles
FTH logo

FTH · Faeth Therapeutics, Inc. · Documents

Track FTH — free

Use FTH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FTH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.03 -0.62 (-5.82%) At close · Nov 13
Rebalance outlook locked
Market Cap
$259.21M
Shares
25.84M
Volume · Nov 13 1.04M Avg daily vol (3M) 482.56K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $21.09M 10-K filed Mar 30, 2026 Quarterly report FY2026 Q3 Net loss $20.4M 10-Q filed Nov 3, 2026 Latest results PIKTOR Fast Track granted as cash reaches $174.8 million 8-K filed Nov 3, 2026
2026
Nov 9
Current report 8-K
PIKTOR plus paclitaxel delivered 33% confirmed ORR in Phase 2

Faeth Therapeutics reported that PIKTOR plus paclitaxel achieved 33% confirmed ORR and 7.4-month preliminary median PFS in advanced endometrial cancer. 2 of 42 patients discontinued for treatment-related adverse events, and pivotal trial design is expected by 1H 2027.

Other events
5 source passages
On November 9, 2026, Faeth Therapeutics, Inc. (the “Company”) made available a presentation to be used to discuss, among other things, the topline clinical data from the Company’s Phase 2 PIK-201 trial evaluating PIKTOR in patients with advanced endometrial cancer. GOG-3111/FTH-PIK-201 is a single-arm Phase 2 study of PIKTOR plus paclitaxel in pathway-altered endometrioid endometrial cancer PIKTOR plus paclitaxel: 33% confirmed ORR and 7.4-month preliminary median PFS after platinum and immunotherapy 2 of 42 (5%) discontinued for treatment-related adverse events Pivotal trial design expected by 1H 2027 Open the document at this passage
Nov 9
Current report 8-K
PIKTOR posts positive Phase 2 results in endometrial cancer

Faeth Therapeutics reported Phase 2 results for PIKTOR plus paclitaxel in advanced endometrioid endometrial cancer: confirmed ORR was 33% (12 of 36), estimated median PFS was 7.4 months, and data support advancing PIKTOR into a Phase 3 registrational trial.

Regulation FD disclosure
4 source passages
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced topline clinical data from its Phase 2 trial (FTH-PIK-201; NCT06463028; GOG-3111) of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation who had received at least one prior line of therapy. As of the October 30, 2026 efficacy data cut, confirmed objective responses were observed in 12 of the 36 efficacy-evaluable patients, for a confirmed objective response rate (ORR) of 33%. In all 42 treated patients, the preliminary Kaplan-Meier estimated median PFS was 7.4 months (95% CI: 5.3 to NR), and the preliminary 6-month PFS rate was 62% (95% CI: 43% to 75%). Data support advancement of PIKTOR development into a Phase 3 registrational trial Open the document at this passage
Nov 3
Current report 8-K
PIKTOR Fast Track granted as cash reaches $174.8 million

Faeth Therapeutics reported $174.8 million in cash, cash equivalents and marketable securities as of September 30, 2026 and $20.4 million net loss. FDA granted Fast Track designation to PIKTOR plus paclitaxel, while Phase 2 topline data are expected by year-end.

Financial results
4 source passages
Cash, cash equivalents and marketable securities were $174.8 million as of September 30, 2026, as compared to $21.2 million as of December 31, 2025. Net loss was $20.4 million, or $0.79 per basic and diluted share, for the quarter ended September 30, 2026, compared with a net loss of $4.6 million, or $3.62 per basic and diluted share, for the quarter ended September 30, 2025. FDA granted Fast Track designation to PIKTOR in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR (PAM) pathway alteration and who have previously been treated with platinum-based chemotherapy and an immune checkpoint inhibitor We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer by year-end, and to reporting initial safety and efficacy data from our PIK-101 trial in HR+/HER2- breast cancer in 2027. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
PIKTOR advances after acquisition-driven loss surge

Faeth Therapeutics, Inc. reported a $206.6 million net loss for the nine months ended September 30, 2026, driven largely by $133.0 million of acquired IPR&D expense, while $174.8 million in cash and marketable securities supports PIKTOR trials through topline data.

Net loss $20.4M Diluted EPS -$0.79
Read from the MD&A section
5 source passages
Effective June 15, 2026, we changed our corporate name from Sensei Biotherapeutics, Inc. to Faeth Therapeutics, Inc. Our net loss was $206.6 million and $16.4 million for the nine months ended September 30, 2026 and 2025, respectively. The increase in our net loss for the nine months ended September 30, 2026 compared to the same prior year period was primarily attributable to $133.0 million of acquired in-process research and development expense recognized in connection with the Acquisition, as well as increased research and development and general and administrative expenses resulting from the integration of Faeth's operations. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $174.8 million. We expect our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements through topline data readouts from both our ongoing Phase 2 trial of PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) and our Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), which we initiated in April 2026. Open the document at this passage
Oct 27
Current report 8-K Events of Oct 23
Director or officer change, or executive pay

Faeth Therapeutics, Inc. expanded its Board from six to seven directors on October 23, 2026, appointing Adam Schayowitz as a Class III director and granting him an option to purchase 25,000 common shares.

May 22
Current report 8-K
Other events AI summary on its way
May 21
Current report 8-K
Other events AI summary on its way
Apr 27
Proxy statement DEF 14A Meeting Jun 10, 2026
Proxy statement AI summary on its way
Apr 16
Proxy statement PRE 14A Meeting Jun 10, 2026
Proxy statement AI summary on its way
Apr 15
Current report 8-K/A Events of Feb 17
Current report AI summary on its way
Mar 30
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $21.09M Diluted EPS -$16.72
2025
Showing 1–50 of 144 documents
Key facts CIK 1829802 CUSIP 81728A207 13F (30d) 41 filings 41 filers Visit website Investor relations